NON SMALL CELL LUNG CANCER

This study tests an experimental drug called TQB2102 for people with advanced non-small cell lung cancer that has a HER2 gene abnormality. The drug is designed to find and attack cancer cells while sparing healthy ones. About 270 adults aged 18-75 with inoperable or metastatic di…

This study tests whether a new combination of two experimental drugs (livmoniplimab and budigalimab) plus chemotherapy works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with untreated metastatic non-squamous non-small cell lung cancer. …

This early-phase study tests a vaccine that targets specific KRAS mutations in advanced non-small cell lung cancer. About 12 participants will receive the vaccine alongside standard chemotherapy and two immunotherapy drugs (nivolumab and ipilimumab). The main goal is to check saf…

This study tests whether adding a new drug (Sigvotatug Vedotin) to standard immunotherapy (pembrolizumab) helps people with advanced non-small cell lung cancer that has high PD-L1 levels. About 714 participants will receive either the combo or pembrolizumab alone. The goal is to …

This study tests whether adding a second immunotherapy drug (domvanalimab) to the standard drug durvalumab can better control stage III lung cancer that hasn't gotten worse after initial chemo-radiation. About 860 adults with a specific type of lung cancer will receive either the…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This early-phase study tests a new experimental treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is given alone or with an immunotherapy drug (atezolizumab) to about 60 adults with advanced solid tumors that have not responded to standard treatme…

This study is for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has stopped responding to targeted pills. It compares a new experimental drug, izalontamab brengitecan, to standard chemotherapy. About 596 participants will be ra…

This study looks at whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to standard immunotherapy can help people with advanced non-small cell lung cancer who have a lower performance status (ECOG 2). About 120 participants will receive either real…

This study compares two treatments for early-stage non-small cell lung cancer in patients who are at high risk for surgery. One group will have a small surgery to remove the tumor, while the other will receive precise, high-dose radiation (SAbR). The goal is to see which approach…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and effective against cancers like ovarian, lung, and breast cancer. About 764 participants will receive the drug, and r…

This study tests a new drug called volrustomig combined with other cancer medicines in people with advanced non-small cell lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 180 adults will take part, and the study is currently recruiting.

This study tests an experimental oral drug, S241656, in people with advanced cancers that have certain gene changes (KRAS, BRAF, and related mutations). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. Abo…

This study is for people with stage III non-small cell lung cancer that cannot be removed by surgery. Researchers want to see if adding another immunotherapy drug (tremelimumab) and extra chemotherapy to the standard drug (durvalumab) can lower the amount of cancer DNA found in t…

This study tests a drug called SAR445877 in people with advanced non-small cell lung cancer that has stopped responding to standard immunotherapy. The goal is to see if the drug can help control the cancer and is safe. About 29 adults will take part at M.D. Anderson Cancer Center…

This study tests two drugs (HLX43 and serplulimab) given before surgery to people with non-small cell lung cancer. The goal is to see if the combination can shrink or eliminate tumors, making surgery more effective. About 60 adults with stage II-IIIB lung cancer will participate.

This early-phase study tests a new drug called BL-M24D1 in 33 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried other tr…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated with immunotherapy and platinum chemo. About 420 adults will be randomly assigned…

This study tests a new drug, ASP5834, in people with advanced solid tumors that have certain changes in the KRAS gene. The goal is to find a safe dose and check for side effects. Some participants with colorectal cancer will also receive another drug called panitumumab. The study…

This study tests an inhaled form of the drug azacytidine, given alongside standard chemotherapy and immunotherapy, for people with early-stage non-small cell lung cancer that can be removed by surgery. The goal is to find the safest and most effective dose and see if this combina…

This study tests whether adding the experimental drug BL-B01D1 to the standard targeted therapy osimertinib works better than osimertinib alone for people with advanced non-small cell lung cancer that has a specific EGFR mutation. About 720 adults with locally advanced or metasta…

This study tests a device that uses focused ultrasound to temporarily open the blood-brain barrier in people with non-small cell lung cancer that has spread to the brain. The goal is to see if this makes standard immunotherapy drugs work better against brain tumors. About 30 adul…

This study tests a drug called lazertinib, given alone or with chemotherapy, before surgery for people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). The goal is to see if the treatment can shrink tumors and improve surgical outcomes. About 160 adul…

This early-phase study tests whether adding Tumor Treating Fields (TTFields) to standard chemoradiation and immunotherapy is safe for people with stage III lung cancer that cannot be removed by surgery. About 30 participants will receive TTFields alongside their usual treatment. …

This early-phase study tests a new drug called GNC-077 in about 20 adults with advanced non-small cell lung cancer or other solid tumors that have spread. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive…

This study tests whether a new drug called RC148, given with chemotherapy, works better than the standard immunotherapy tislelizumab plus chemotherapy for people with advanced squamous non-small cell lung cancer who haven't had treatment yet. About 574 adults aged 18-75 will take…

This study tests whether a transplant of healthy gut bacteria (from donor stool) can help the immune system better fight lung cancer when combined with the immunotherapy drug pembrolizumab. It is for people with a type of advanced lung cancer (PD-L1 positive NSCLC) that has stopp…

This study tests a new drug, SHR-A2102, combined with other cancer treatments given before and after surgery for non-small cell lung cancer that can be removed. About 300 adults aged 18-70 with good organ function will participate. The goal is to see if the combination helps dest…

This study tests the safety and effectiveness of combining two drugs, lorlatinib and ramucirumab, for people with advanced ALK-rearranged non-small cell lung cancer. About 56 participants will receive different doses to find the best one with the fewest side effects. The goal is …

This study tests whether combining two drugs, GEN-725 and Dositinib, can shrink tumors or slow cancer growth in people with advanced EGFR-mutant non-small cell lung cancer. About 110 adults whose cancer has spread or can't be removed by surgery will take part. The goal is to cont…

This study tests a drug called zanidatamab in people with advanced cancers (lung, sarcoma, head & neck, colorectal, or endometrial) that have a specific HER2 gene change. The goal is to see if the drug can shrink tumors. About 105 participants will receive the drug by IV every 3 …

This early-stage study tests a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. About 101 people with certain cancers…

This study tests whether adding a traditional Chinese herbal formula called HGXJT to standard immunotherapy can help control lung cancer that has spread to the bones. About 82 adults with this type of lung cancer will receive either the herbal medicine or a placebo during their f…

This program provides early access to the investigational drug zidesamtinib for people with advanced ROS1-positive non-small cell lung cancer or other solid tumors who have run out of standard options and cannot join a clinical trial. Participants must have tried at least one pri…

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent lung cancer from coming back after surgery. About 868 people with stage II to IIIB non-small cell lung cancer who have had their tumor completely remov…

This study tests whether adding a nitroglycerin patch (a heart medication) to standard radiation therapy can better shrink brain tumors in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer) that has spread to the brain. About 74 adults will receiv…

This study tests whether a new drug, sacituzumab tirumotecan, given alone or with another drug (osimertinib) before surgery, can shrink tumors in people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer). The goal is to see if this approach makes surger…

This study is testing a new drug called QL1706 combined with chemotherapy before surgery for people with a certain type of lung cancer (non-small cell lung cancer, stages IIB to IIIB). About 30 participants will receive the drug combo for three cycles, then have surgery to remove…

This study tests an experimental drug called STX-721 in people with advanced non-small cell lung cancer that has specific gene changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug shrinks tumors. About 251 participants will receive the dr…

This study tests a combination of the drug toripalimab and a freezing technique called cryoablation in people with advanced non-small cell lung cancer whose cancer has started to grow again after initial immunotherapy. The goal is to see if this approach can help control the canc…

This study tests a new drug (ES102) combined with an immunotherapy (toripalimab) in 40 adults with advanced non-small cell lung cancer that has not responded to prior treatments. The goal is to see if the combination can shrink tumors or stop them from growing. Participants must …

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and then infu…

This study is for people with early-stage non-small cell lung cancer who have finished standard treatment. A simple blood test looks for tiny bits of cancer DNA (ctDNA) that might mean the cancer could come back. If the test is positive, participants receive the drug durvalumab t…

This early-stage study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study tests whether using a special surgical sealant (Progel Platinum) on stapled lung tissue during surgery for non-small cell lung cancer can reduce the time patients need a chest tube after surgery. About 160 adults having minimally invasive lung lobe removal will be rand…

This early-phase study tests a new drug called anvumetostat, alone or with other treatments, in adults with advanced chest cancers (like lung cancer) that have a specific genetic change (MTAP-deletion). The main goals are to find the safest dose and check for side effects. About …

This study tests a new drug called YL202 combined with other anti-tumor treatments in people with advanced solid tumors, including breast and lung cancer. The goal is to see if the combination is safe and can shrink tumors. About 414 adults aged 18-75 who have already tried stand…

This study tests whether a new drug, PF-08634404, combined with chemotherapy works better than the current standard treatment (pembrolizumab plus chemo) for adults with advanced non-small cell lung cancer. About 1,410 participants will be randomly assigned to receive either the n…

This study tests two drugs, envafolimab and lenvatinib, together in people with advanced solid tumors (lung, kidney, or liver cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors better than current options. About 170 adu…

This study tests a new daily pill, VS-7375, in people with advanced cancers (pancreatic, lung, colorectal, and others) that have a specific genetic change called KRAS G12D. The trial will first find the safest dose of VS-7375 alone, then test it in combination with other cancer d…

This early-stage study is testing a new drug, AOH1996, in adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and understand side effects. The drug works by blocking certai…

This study tests a new two-drug combination (trastuzumab deruxtecan plus pembrolizumab) against standard chemotherapy plus pembrolizumab as a first treatment for people with advanced HER2-positive, PD-L1 low non-small cell lung cancer. About 686 adults will take part to see if th…

This study tests whether a new drug combination (datopotamab deruxtecan plus rilvegostomig) or rilvegostomig alone works better than the current standard treatment (pembrolizumab) for people with advanced non-squamous lung cancer that has high PD-L1 levels. About 675 adults with …

This study tests a new experimental drug, BNT116, for people with advanced non-small cell lung cancer. The goal is to find safe doses when given alone or with other cancer treatments. About 320 participants will take part in this early-phase trial.

This early-phase study tests a new drug called PT0511 in adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have a specific KRAS mutation or amplification. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors…

This early-phase study tests an experimental drug called PRTH-101, given alone or with the immunotherapy pembrolizumab, in adults with advanced or metastatic solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug helps…

This study tests a new approach for people with early-stage (IB to III) non-small cell lung cancer that can be removed with surgery. Before surgery, patients receive a combination of low-dose radiation and two immunotherapy drugs (ipilimumab and nivolumab). The goal is to see if …

This study tests an experimental oral drug (7HP349) combined with standard immunotherapies (ipilimumab and nivolumab) in adults with advanced solid tumors like melanoma, lung, kidney, or liver cancer that have not responded to prior treatments. The goal is to find safe doses and …

This study looks at whether adding a low dose of radiation to the liver can help immunotherapy work better for people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 adults whose cancer is being treated with standard immunotherapy will also rece…

This study tests a new drug, taletrectinib, against the current standard drug, crizotinib, in people with a specific type of advanced lung cancer (ROS1-positive NSCLC) who have not had targeted therapy before. About 194 participants will be randomly assigned to take either taletr…

This early-phase trial tests a new treatment for people with advanced non-small cell lung cancer that has specific genetic changes (EGFR, ALK, ROS1, or HER2). The treatment uses a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), which are boosted in the la…

This study looks at whether adding radiotherapy to standard immunotherapy after surgery can help people with stage 3 non-small cell lung cancer that has spread to multiple lymph nodes. About 60 adults aged 18 to 75 will receive the combined treatment. The goal is to see if it del…

This program offers early access to an investigational drug called telisotuzumab adizutecan for people with solid tumors who have no other suitable treatment options and cannot join a clinical trial. A doctor must decide if the potential benefits outweigh the risks. Availability …

This study tests a new combination of two drugs, DZD6008 and sunvozertinib, in people with advanced non-small cell lung cancer that has certain EGFR mutations. The goal is to see if the combination is safe and can shrink tumors. About 200 adults will take part. This is an early-p…

This study tests whether a daily pill called zongertinib can help prevent lung cancer from returning after surgery in people with early-stage (Stage II-IIIB) non-small cell lung cancer that has a specific HER2 mutation. About 400 adults who have had their tumor completely removed…

This study tests whether adding the experimental drug MK-1084 to the standard immunotherapy pembrolizumab helps people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 600 adults with newly diagnosed, adv…

This early-phase study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…

This study tests a new drug combination (ivonescimab plus docetaxel) in 70 adults with advanced non-small cell lung cancer who had a good long-term response to initial immunotherapy but still have cancer DNA in their blood. The goal is to see if this approach can delay cancer pro…

This study is for people with stage II to IIIA non-small cell lung cancer who have had surgery to remove the tumor. Participants will receive the drug cemiplimab (an immunotherapy) or no additional treatment. The goal is to see if cemiplimab can delay or prevent the cancer from r…

This study tests a new pill called dositinib for people with advanced lung cancer that has a specific genetic change (EGFR mutation). The goal is to find the safest dose and see if it shrinks tumors. About 153 adults aged 18-75 who have tried other treatments without success can …

This early-stage study tests an experimental drug called DZD6008 in people with advanced non-small cell lung cancer that has specific EGFR gene mutations. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 140 adults whose c…

This study tests whether a new targeted pill (MK-1084) combined with an immunotherapy (pembrolizumab) can help people with a specific KRAS-mutated advanced lung cancer live longer without their cancer growing, compared to standard chemo plus immunotherapy. About 675 adults with n…

This study tests whether a combination of two targeted drugs (IN10018 and D-1553) works better than standard chemotherapy plus immunotherapy for people with a specific genetic mutation (KRAS G12C) in advanced non-small cell lung cancer. About 400 adults who have not had prior tre…

This study tests a daily pill called sunvozertinib in people with advanced non-small cell lung cancer that has certain rare EGFR gene mutations and has not been treated before. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Abou…

This study tests a new drug called BNT327 combined with chemotherapy and other agents in people with advanced non-small cell lung cancer who have not had prior treatment. About 1,260 participants will be enrolled globally. The goal is to see if the combination shrinks tumors and …

This early-stage study tests a new treatment for people with advanced lung cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells (T cells) that have been modified in a lab to better recognize and attack cancer cells. The main goal …

This early-stage trial tests a treatment called GC101 TIL, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced non-small cell lung cancer. About 20 adults whose cancer has not responded to standard therapies will receive the cells and be mon…

This study looks at whether adding a precise form of radiation called stereotactic radiosurgery (SRS) to standard drug therapy can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain m…

This study tests an experimental daily pill, CP-383, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the best dose and see if the drug can slow or stop cancer growth. About 150 participants will take the pill daily a…

This study tests whether adding the experimental drug SHR-A2009 to the standard pill aumolertinib works better than aumolertinib alone for people with advanced lung cancer that has an EGFR mutation. About 576 adults who have not had prior treatment will take part. The main goal i…

This early-stage study tests a new drug called IDE034 in 150 adults with advanced solid tumors (like lung, ovarian, or colon cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors…

This phase 3 study tests whether adding the diabetes drug metformin to standard targeted therapy (tyrosine kinase inhibitors) can help control advanced non-small cell lung cancer with EGFR mutations. About 312 adults with stage IIIB or IV lung cancer will receive either metformin…

This study is for adults with early-stage non-small cell lung cancer who are scheduled for surgery. Researchers want to see if adding a third drug to the standard immunotherapy (cemiplimab) and chemotherapy helps shrink tumors more before surgery and keeps cancer away longer. Abo…

This study tests two new drug combinations (ivonescimab with Dato-DXd or osimertinib) in people with advanced EGFR-mutant non-small cell lung cancer that has stopped responding to standard treatments. The goal is to find the safest dose and see if the combinations can shrink tumo…

This study tests a combination of three drugs (datopotamab deruxtecan, carboplatin, and pembrolizumab) in people with non-small cell lung cancer that has spread to the brain and has not been treated yet. The goal is to see if the treatment shrinks brain tumors. About 46 adults wi…

This early-phase study tests a new drug called OCT-598 in people with advanced solid tumors (breast, lung, prostate, head/neck, or stomach cancer). The main goals are to find a safe dose and check for side effects when given alone or with standard treatments. About 51 adults will…

This study tests whether adding a drug called tarlatamab to standard radiation therapy is safe and effective for cancers that have a protein called DLL3, such as certain lung cancers, melanomas, and bladder cancers. About 30 adults with advanced or returning cancers will receive …

This study tests whether combining a targeted drug (adagrasib) with precise radiation (stereotactic radiosurgery) can better control brain tumors in people with a specific type of advanced lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain metastases will…

This study tests whether adding a new targeted drug (HER3-DXd) to standard immunotherapy (pembrolizumab) with or without chemotherapy works better for people with advanced non-small cell lung cancer that hasn't been treated yet. About 90 participants will receive different treatm…

This early-stage study is testing a new drug that delivers radiation directly to cancer cells in adults with advanced solid tumors, including pancreatic, lung, breast, and colorectal cancers. The main goal is to check the drug's safety and find the right dose. About 180 participa…

This early-phase study tests whether adding carotuximab to the standard drug osimertinib is safe and tolerable for people with advanced EGFR-mutated non-small cell lung cancer that has stopped responding to previous treatments. About 60 adults with stage IV or recurrent lung canc…

This study is for people with a type of lung cancer that cannot be treated with surgery or standard chemo-radiation. It tests adding new drugs (DNA damage repair inhibitors) to standard radiation therapy, followed by a year of immunotherapy. The main goal is to find the safest do…

This study tests whether giving the immunotherapy drug durvalumab after surgery and chemotherapy can help prevent non-small cell lung cancer from returning in people with stage IIB to IIIB disease. About 290 participants will first receive durvalumab plus chemotherapy before surg…

This study compares two types of minimally invasive lung cancer surgery: robot-assisted (RATS) and video-assisted (VATS). About 1,124 people with early-stage non-small cell lung cancer will take part. The goal is to see if robot-assisted surgery is as good as video-assisted surge…

This study is for people with breast or lung cancer that has spread to 1 to 5 spots in the body. It tests whether giving a special, high-dose radiation treatment (SBRT) to all those spots, along with standard care, can keep the cancer from getting worse longer than standard care …

This study looks at whether a simple blood test can find tiny bits of cancer DNA left behind after lung cancer surgery. People whose blood shows these signs of leftover cancer will get extra treatment with chemotherapy and immunotherapy. The goal is to see if this approach can st…

This study tests a new drug called MCLA-129 in people with advanced solid tumors like lung, head and neck, or colorectal cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to attach to two cancer-related proteins (EGFR and c-Met) to b…

This early-phase study tests a new drug called LNCB74 in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. LNCB74 is an antibody-drug conjugate designed to deliver a cancer-killing agent dir…

This study looks at how well the drug pembrolizumab (with or without chemotherapy) works in Black patients with advanced non-small cell lung cancer. About 318 participants will be followed to see how long they live or how long the cancer stays under control. The goal is to find m…

This study tests a combination of two drugs (BL-B01D1 and a PD-1 antibody) in adults with advanced or spreading non-small cell lung cancer, nasopharyngeal cancer, or other solid tumors. The goal is to see if the combo can shrink tumors and control the disease. About 570 participa…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

This study tests whether adding a special type of radiation (SFRT) to standard treatment can help control non-small cell lung cancer that has started to grow again after initial therapy. About 25 adults with up to 5 growing tumors will receive SFRT to those spots while continuing…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or come back. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the lab to include a protein (IL…

This study looks at whether giving radiation to the chest after surgery can help people with stage III lung cancer who still have some cancer left after chemo and immunotherapy. About 118 adults will be randomly assigned to get either standard follow-up care or additional radiati…

This study tests a new drug called AU-007 in people with advanced solid tumors (cancers that have spread). The drug is designed to help the immune system fight cancer more effectively. About 159 participants will receive AU-007 alone or with other immune-boosting drugs. The goal …

This study looks at whether adding surgery or radiation to the main tumor can help people with advanced EGFR-mutant lung cancer who have already responded well to a combination of targeted therapy (osimertinib) and chemotherapy. About 70 adults will receive local treatment and be…

This study tests a new drug, WSD0922-FU, in 40 adults with advanced non-small cell lung cancer that has a specific genetic change (C797S mutation) and has stopped responding to the standard first treatment, osimertinib. The goal is to see if the drug can shrink tumors or slow the…

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors (like lung, head and neck, or colon cancer) that have stopped responding to standard therapies. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participant…

This study tests a new drug called YL202 in about 100 people with advanced solid tumors, including lung, colorectal, and cervical cancers. The goal is to see if YL202 can shrink tumors and control the disease. Participants must be 18 or older with a BMI between 18 and 32.

This study tests two experimental drugs, SI-B001 and SI-B003, with or without chemotherapy, in people with advanced non-small cell lung cancer. The goal is to find safe doses and see if the combination can shrink tumors. About 160 adults aged 18 to 75 are being recruited.

This study compares an experimental drug, telisotuzumab vedotin, to a standard chemotherapy (docetaxel) in adults with a specific type of advanced non-small cell lung cancer that has already been treated. The cancer must have high levels of a protein called c-Met. About 698 parti…

This study tests an experimental drug called VMD-928, taken as a pill, alone or with pembrolizumab (an immunotherapy), in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shri…

This early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have MAPK pathway mutations (like KRAS or BRAF) and who have not responded to or exhausted other treatments. The goal is to offer compassionate access to this medication, either alo…

This early-stage study tests a new drug called CTX-8371 in people with advanced cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 adults with certain types of lung, breast, lymphoma, head and neck,…

This study tests a combination of two drugs, HLX43 and serplulimab, in people with advanced solid tumors (including non-small cell lung cancer) that have not responded to standard treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. About 105 ad…

This study tests a combination of two experimental drugs, DZD9008 and AZD4205, in people with advanced non-small cell lung cancer that has EGFR mutations and has stopped responding to standard treatments. The goal is to see if the combination is safe and can shrink tumors. About …

This early-phase study tests a new drug (BMS-986340) alone or with other cancer treatments in people with advanced solid tumors like lung, breast, and colon cancer. The main goal is to find safe doses and check for side effects. About 949 participants will join to see if the drug…

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…

This early-phase study tests a new oral drug, BGB-43395, that blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced hormone-positive, HER2-negative breast cancer or other solid tumors that have spread. The study aims to find the safest dose and see …

This study tests two experimental drugs, BNT326 and BNT327, together in people with advanced non-small cell lung cancer (NSCLC) that has spread or come back. The goal is to find the best dose and see if the combination can shrink tumors and control the disease. About 420 adults w…

This study tests whether removing extra safety margins in adaptive stereotactic radiotherapy can lower the risk of breathing problems for people with early-stage non-small cell lung cancer or limited lung metastases. About 130 participants will be randomly assigned to standard or…

This study is testing a new drug combination (YL201 and ivonescimab) in people with advanced solid tumors, including certain lung cancers. The goal is to see if the combination is safe and can shrink tumors. About 260 adults will take part, and the study is currently recruiting.

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific TP53 Y220C mutation. The trial has two parts: first, finding the safest dose, and then seeing how well the drug works alone or with another drug (pembrol…

This study tests a treatment that uses immune cells taken from a patient's own lung tumor. These cells are grown in large numbers in a lab and then given back to the patient to attack the cancer. The trial enrolls 30 adults with advanced non-small cell lung cancer that has worsen…

This study tests a combination of two drugs—tulmimetostat (an EZH2 inhibitor) and pembrolizumab (an immunotherapy)—in people with advanced non-small cell lung cancer whose disease has worsened after initial treatment. About 66 veterans will receive this therapy to see if it can s…

This study tests whether a new drug, SKB264, combined with pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with advanced non-squamous lung cancer that lacks the PD-L1 protein. About 432 adults with stage IIIB/IV cancer who haven't had prior tre…

This study offers ongoing access to dabrafenib and/or trametinib for patients with certain cancers (like melanoma or lung cancer) who were already benefiting from these drugs in a previous Novartis or GSK trial. The main goal is to track long-term safety and side effects. About 1…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses a patient's own immune cells, which are …

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults with se…

This early-phase study tests a new drug that delivers radiation directly to cancer cells in people with advanced solid tumors (like lung, colon, head and neck, pancreatic, stomach, or kidney cancer) that have stopped responding to standard treatments. The main goals are to check …

This study tests an experimental drug called telisotuzumab vedotin in adults with a specific type of advanced lung cancer (non-small cell lung cancer that has a high level of a protein called c-Met). About 150 participants will be randomly assigned to one of three different dose …

This study tests adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy for people with advanced non-squamous non-small cell lung cancer whose PDL1 is below 50%. The trial has two parts: first, finding the safest dose, then comparing the new combin…

This early-phase study tests a new treatment called 177Lu-RAD204, which combines a radioactive particle with an antibody that targets a protein (PD-L1) found on many cancer cells. The goal is to see if it is safe and how it spreads in the body. About 30 adults with advanced lung,…

This study tests whether adding a maintenance drug (MK-2870) after initial chemotherapy and immunotherapy can help people with advanced squamous lung cancer live longer. About 851 participants will receive standard treatment plus either MK-2870 or a placebo. The goal is to see if…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study tests whether using a protein-based test to guide treatment can help people with advanced non-small cell lung cancer live longer without their cancer getting worse. About 56 adults with stage IIIC or IV lung cancer will be randomly assigned to either standard therapy o…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 16…

This study tests a new approach for people with advanced lung cancer whose disease has worsened after initial treatment. It combines a virus that attacks cancer cells (Olvi-Vec) with chemotherapy and an immunotherapy drug, and compares it to standard chemotherapy alone. The goal …

This study tests a new oral drug, TNG456, in people with advanced solid tumors that lack the MTAP gene. The drug aims to slow or stop tumor growth. The trial has two parts: first finding the best dose, then testing it in specific cancers like lung cancer and brain tumors. About 1…

This study tests whether a special type of radiation (SFRT) given together with the immunotherapy drug tislelizumab and standard chemotherapy can shrink stage III lung cancer enough to allow surgery. About 30 adults with initially unresectable non-small cell lung cancer will rece…

This study tests an experimental drug called sunvozertinib against a placebo in people with a specific type of lung cancer (non-small cell) that has certain gene changes (EGFR exon20 insertion or PACC mutations). Participants must have had their tumor completely removed by surger…

This study tests a combination of furmonertinib (a targeted pill), chemotherapy given into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR mutation) that has spread to the brain and its lining. About 30 adults who have not had prior tr…

This study tests whether adding the targeted drug MK-1084 to standard immunotherapy (pembrolizumab) after surgery can keep KRAS G12C-mutant lung cancer from coming back. About 400 adults with stage IIA-IIIB non-small cell lung cancer who have had complete tumor removal will recei…

This study tests a drug called pyrotinib as a first treatment for people with advanced non-small cell lung cancer that has a specific change in the HER2 gene. About 18 adults with stage IIIB or IV cancer who haven't had prior treatment will take pyrotinib pills. The goal is to se…

This study tests several new drug combinations given before and after surgery for early-stage non-small cell lung cancer. About 630 people with stage II to IIIB lung cancer will receive these treatments to see if they improve outcomes. The goal is to find safer and more effective…

This study tests whether adding ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer whose disease worsened after prior immunotherapy. About 536 adults aged 18–75 with good performance status will be randomly assigned to receive e…

This study tests a new drug called ivonescimab against the current standard treatment, pembrolizumab (Keytruda), for people with advanced lung cancer that has spread. It includes 780 adults whose tumors have high levels of a protein called PD-L1. The goal is to see if ivonescimab…

This study tests a new drug called GI-101, alone or with other cancer drugs (pembrolizumab or lenvatinib), in people with advanced solid tumors that have spread. The goal is to see if it is safe and helps control the cancer. About 317 adults with certain cancers like lung, kidney…

This study tests a new drug called LY4052031 in people with advanced or metastatic solid tumors, including bladder, breast, lung, and other cancers. The goal is to find safe doses and see if the drug can shrink tumors. About 420 participants will take part over up to 4 years.

This study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) as a first treatment for people with advanced non-small cell lung cancer that has certain rare gene changes (EGFR PACC mutations). About 480 participants worldwide will be random…

This study tests a new drug called TNG260, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have a specific genetic change (STK11 mutation). The main goals are to find the best dose and check safety and effectiveness. About 126 adult…

This study tests whether adding the drug envafolimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with stage III non-small cell lung cancer that can be surgically removed. About 390 adults will receive either the combination or a placebo plu…

This early-phase study tests a new drug called tolododekin alfa (ANK-101) that is injected directly into tumors. It is for people with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose, both al…

This study tests whether using MRI scans to guide radiation therapy can reduce side effects and improve outcomes for people with stage 3 non-small cell lung cancer. About 490 participants will receive radiation, chemotherapy, and immunotherapy, with half getting MRI-guided radiat…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take the drug alon…

This study tests a new drug called pumitamig combined with standard chemotherapy for people with advanced non-small cell lung cancer that has worsened after initial treatment. About 60 participants will receive the combination to see if it is safe and shrinks tumors. The goal is …

This study is for people with early-stage non-small cell lung cancer that can be removed with surgery. It tests different drug combinations before and after surgery, chosen based on the tumor's specific biomarkers. The goal is to see if these targeted treatments can shrink or eli…

This early-stage study tests a new drug called KIVU-107 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to find a safe dose and check for side effects. About …

This early-phase trial tests a new drug that delivers radiation directly to cancer cells by targeting a protein called Nectin-4. It is for people with advanced solid tumors (like bladder, breast, lung, or cervical cancer) that have not responded to prior treatments. The study aim…

This study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has low PD-L1 levels. It tests whether a reduced dose of chemotherapy combined with an immunotherapy drug can be better tolerated—meaning fewer people have to stop che…

This study tests a lower dose of the targeted drug osimertinib in people with advanced EGFR-positive non-small cell lung cancer. The goal is to see if it is safe and still controls the cancer while possibly reducing side effects. About 58 adults who have not had prior EGFR-target…

This study is for people with a type of lung cancer that has spread to a few other places in the body and has specific gene changes. Participants will either continue taking their targeted therapy pills alone or also receive radiation to the cancer spots. The goal is to see if ad…

This study is for people with advanced or recurrent non-small cell lung cancer who have not had prior treatment. It tests two different dosing schedules of a subcutaneous (under-the-skin) form of nivolumab, given together with intravenous ipilimumab and chemotherapy. The main goa…

This study tests a new combination for people with advanced non-small cell lung cancer that no longer responds to standard immunotherapy or chemotherapy. The treatment adds EXL01, a healthy gut bacterium, to the immunotherapy drug nivolumab. The goal is to see if this combination…

This study tests a new oral drug, sutetinib maleate, in people with advanced non-small cell lung cancer that has uncommon EGFR mutations. The goal is to see if the drug can shrink tumors or slow cancer growth. About 66 adults with measurable tumors and good organ function will ta…

This early-phase trial tests a new type of immune cell therapy (CAR-NK cells) for people with advanced non-small cell lung cancer that has not responded to standard treatments. The cells are designed to target two cancer markers at once, chosen based on each patient's tumor profi…

This study is testing an experimental drug called CGT4255 in about 100 adults with advanced solid tumors that have specific changes in the ERBB2 gene or too much HER2 protein. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors, incl…

This study tests whether adding a precise, high-dose radiation treatment to the liver (L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will receive either standard drug therapy alone or stand…

This study tests a drug called anlotinib in people with non-small cell lung cancer who still have cancer cells after surgery and chemotherapy. The goal is to see if the drug can prevent the cancer from coming back. About 64 adults will take the drug and be monitored for recurrenc…

This study tests a treatment plan for people with stage III non-small cell lung cancer. First, patients get three rounds of chemotherapy plus the immunotherapy drug atezolizumab. Then, a team decides if surgery is possible. Those who have surgery get more atezolizumab afterward; …

This study tests a new drug called andamertinib, alone or with chemotherapy, for people with advanced lung cancer that has certain rare gene changes (atypical EGFR mutations). The goal is to see if the drug shrinks tumors and is safe. About 40 adults who have not had prior treatm…

This study tests a new drug called TUB-040 in people with advanced ovarian cancer or a type of lung cancer that has stopped responding to standard treatments. The drug works like a guided missile, delivering a cancer-killing agent directly to tumor cells that have a specific mark…

This early-stage study tests a new drug called BBO-8520 in about 350 adults with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participa…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors, including colorectal, pancreatic, lung, ovarian, and mesothelioma cancers. The treatment uses the patient's own immune cells, modified to target cancer cells while sparing healthy ones. The s…

This study tests whether adding chemotherapy to standard immunotherapy (pembrolizumab) can improve outcomes for people with advanced lung cancer. Researchers will use a blood test that detects cancer DNA (ctDNA) to decide when to add chemo. About 230 participants will be enrolled…

This study is for adults with advanced non-squamous non-small cell lung cancer whose disease has worsened after initial treatment. Researchers want to see if combining carboplatin, paclitaxel, and ramucirumab can shrink tumors or slow their growth. About 59 participants will rece…

This study tests a new type of proton therapy called Hypervision Proton Surgery (HyPROS) for people with early-stage non-small cell lung cancer. The goal is to see if a single, high-dose treatment can safely control the tumor. About 12 participants will be enrolled, and researche…

This study tests a new drug called HLX17 to see if it works like the approved cancer drug Keytruda. It is for adults who have had surgery to remove certain cancers (lung, melanoma, or kidney cancer). The goal is to compare how the body processes HLX17 versus Keytruda, and to chec…

This study tests several new drug combinations in people with advanced non-small cell lung cancer that has spread. The goal is to see if these combinations are safe and can shrink tumors. About 278 adults with good performance status and measurable tumors will participate across …

This study tests a new combination of two drugs, ZG005 and gecacitinib, in people with advanced non-small cell lung cancer that has not responded to previous treatments. The goal is to see if the combination is safe and can shrink tumors. About 50 adults aged 18-75 will take part…

This study tests whether adding targeted radiotherapy to the usual drug treatment can slow the growth or spread of lung cancer in people with advanced non-small-cell lung cancer. About 320 participants whose cancer has started to grow in a few spots while on first-line therapy wi…

This study tests a new drug, HMBD-501, in people with advanced cancers (melanoma, lung, or breast) that have stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 180 adults will take part in two phases: first to check s…

This study tests whether fingolimod, a drug currently used for multiple sclerosis, can help control advanced lung cancer in people who have already tried standard treatments. About 38 adults with non-small cell or small cell lung cancer will take a daily pill. The main goals are …

This program provides early access to the investigational drug neladalkib for people with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. Participants must be at l…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors (like lung, breast, or colon cancer) who have run out of standard treatments. The main goals are to check safety and find the right dose. About 10…

This study is for people with advanced non-small cell lung cancer that does not have the PD-L1 marker. It compares two treatments: one immune therapy drug plus chemotherapy versus two immune therapy drugs plus chemotherapy. The goal is to see if the two-drug combination leads to …

This study tests whether adding valemetostat to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer that has high PD-L1 levels. About 137 adults who have not had prior treatment for their advanced cancer will be randomly assigned to rece…

This early-phase study tests a new drug, LY3962673, in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The study includes up to 630 participants with pancreatic, lung, or colorectal cancer that has not responded to prior treatment. The goal…

This study tests whether a new drug called ivonescimab, when combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that has spread. About 1,600 adults with stage IV lung c…

This study is for people with a certain type of lung cancer (stage II to IIIB) that was not completely eliminated by chemotherapy and immunotherapy before surgery. After surgery, participants will receive either the standard immunotherapy (pembrolizumab) alone or with an experime…

This study tests whether adding an experimental drug (Dato-DXd) to a standard targeted therapy (osimertinib) helps people with advanced EGFR-mutant lung cancer live longer without their cancer growing. About 582 adults with stage IIIB/IV non-small cell lung cancer will receive ei…

This study tests an experimental drug called AZD6750, which is designed to guide the immune system to attack cancer cells. It is for adults with advanced solid tumors like melanoma, lung cancer, or breast cancer that have not responded to other treatments. The study will first fi…

This early-phase study tests a new oral drug, DO-2, in adults with advanced solid tumors (like lung cancer) that have a specific MET gene change and no standard treatment options left. The main goal is to check the drug's safety and find the right dose. About 55 participants will…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This study tests whether adding the experimental drug SKB264 to the standard targeted therapy osimertinib works better than osimertinib alone for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer). About 420 adults who have …

This study is testing whether a short course of low-dose radiation followed by immunotherapy and chemotherapy can shrink tumors before surgery in people with stage II to III non-small cell lung cancer. The goal is to see if this approach makes surgery more effective and reduces t…

This study tests the drug cabozantinib in people with advanced non-small cell lung cancer that has certain gene changes (RET, ROS1, NTRK fusions, or increased MET or AXL activity). The goal is to see if the drug can shrink tumors and stop them from growing. About 86 participants …

This study tests whether giving immunotherapy and chemotherapy before radiation can help veterans with stage III lung cancer that cannot be removed by surgery. About 25 participants will receive the treatment combination. The goal is to see if this approach improves how long the …

This study tests two higher doses of the drug furmonertinib, either alone or combined with chemotherapy, in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease got worse after initial treatment with a similar drug. The goal is to see if these options can …

This study is for people with non-small cell lung cancer that has spread to the brain (1 to 10 spots). Researchers want to see if using MRI-guided radiation without the usual extra safety margins can still be effective while lowering the risk of brain tissue damage. About 168 adu…

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that got worse after immunotherapy. About 630 adults will be randomly assigned to receive either the new drug or chemo every three…

This study tests whether giving radiation to the main lung tumor before starting targeted pills (TKI) can delay cancer progression in people with advanced, driver-mutated non-small cell lung cancer. About 34 participants who have not had prior treatment will receive radiation to …

This early-phase study tests a treatment where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a specific marker called NY-ESO-1. The therapy is given as a one-time infusion to adults with advanced or spreading cancers lik…

This study tests a new drug, iruplinalkib, in 20 adults with advanced ALK-positive lung cancer that got worse or caused side effects after treatment with lorlatinib. Researchers will track how long the drug controls the cancer and monitor safety in real-world settings. The goal i…

This study tests a new drug, telisotuzumab adizutecan, against standard care for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened after taking a modern targeted therapy. About 430 adults will take part. T…

This early-phase study tests a new drug called EPI-326 in people with advanced lung cancer (with a specific EGFR mutation) or head/neck cancer. The main goals are to check safety and find the best dose. About 110 participants will receive the drug to see if it can shrink tumors a…

This study tests a new drug called FMC-376 in people with advanced solid tumors that have a specific genetic change (KRAS G12C). The goal is to find a safe dose and see if the drug can shrink tumors. About 400 adults whose cancer has worsened after standard treatments will take p…

This study tests a new drug, NVL-655, against the current standard treatment alectinib for people with ALK-positive advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if NVL-655 can delay cancer growth or death longer than alectinib. About 45…

This early-stage study is testing a new drug, SIM0610, for the first time in people. It aims to see if the drug is safe and tolerable for adults with advanced solid tumors, including lung, colorectal, head and neck, and liver cancers. The study will also look for early signs that…

This study tests whether combining an immunotherapy drug (atezolizumab), an immune booster (BDB001), and targeted radiation can help control advanced solid tumors. About 247 adults with cancers like pancreatic, lung, or breast cancer will receive the treatment. The goal is to see…

This study tests whether adding BIO 300 to standard chest radiation can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). About 25 adults will receive the combination and b…

This study tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy works better than the current standard (pembrolizumab plus chemotherapy) for people with advanced non-squamous lung cancer whose tumors have PD-L1 levels of 1% or higher…

This study tests whether a new drug called rilvegostomig, when added to standard chemotherapy, helps people with advanced squamous non-small cell lung cancer live longer or delay cancer growth. It is for people whose tumors have a specific protein (PD-L1). About 880 participants …

This early-stage trial tests an experimental drug called MRTX1719 in people with advanced solid tumors that have a specific genetic change (loss of the MTAP gene). The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 adults with…

This study tests a combination of one chemotherapy drug and the immunotherapy pembrolizumab for people with advanced non-small cell lung cancer who have a lower performance status (ECOG PS 2), meaning they need to rest up to half the day. The goal is to see if this treatment is s…

This study tests whether adding the targeted drug vebreltinib to standard chemotherapy helps people with advanced MET-positive non-squamous lung cancer live longer without their cancer growing. About 300 adults who have not had prior treatment will be randomly assigned to receive…

This study tests whether a new drug, divarasib, combined with the immunotherapy pembrolizumab works better than standard chemotherapy plus pembrolizumab for people with a specific genetic type of advanced lung cancer (KRAS G12C). About 600 adults who have not had prior treatment …

This study tests whether early, specialized heart monitoring and care can help people with advanced lung cancer live longer and have fewer heart-related side effects while receiving standard cancer treatments like radiation, chemotherapy, and immunotherapy. About 524 adults with …

This study tests a new medicine called PF-08634404 combined with other cancer drugs in people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The main goals are to check safety, side effects, and whether the combination can shrink tumors…

This study tests an experimental drug called STK-012, alone or with standard chemotherapy, in people with advanced solid tumors, especially a type of lung cancer called non-small cell lung cancer (NSCLC). The goal is to see if STK-012 is safe and can shrink tumors. About 364 adul…

This study tests whether giving the drug trastuzumab deruxtecan before routine surgery can shrink tumors in people with a specific type of lung cancer (HER2-amplified or HER2-mutated non-small cell lung cancer). About 14 adults with stage II to IIIB lung cancer will receive the d…

This early-stage study tests a new drug, LY4050784, in people with advanced solid tumors that have a specific genetic change (SMARCA4/BRG1). The goal is to see if the drug is safe and works, either alone or with other cancer treatments. About 340 participants will join, and the s…

This study tests a new drug called ivonescimab combined with standard chemotherapy and precise radiation (SRS) for people with non-small cell lung cancer that has spread to the brain. The goal is to find a safe dose and see if it helps control the brain tumors. About 53 adults wi…

This study is testing whether adding an experimental drug called nelmastobart to standard chemotherapy (docetaxel) can help control advanced lung cancer that has stopped responding to previous treatments. The trial will enroll 62 adults with advanced non-small cell lung cancer wh…

This study is testing a new two-drug combination (BL-B01D1 + SI-B003) for people with advanced non-small cell lung cancer or nasopharyngeal carcinoma that has spread. The main goal is to see if the treatment is safe and if it shrinks tumors. Researchers will enroll about 121 adul…

This study is testing an experimental drug called DRP-104 for people with advanced non-small cell lung cancer that has specific genetic changes (NFE2L2 or KEAP1) and has stopped responding to standard chemotherapy and immunotherapy. The main goal is to see if the drug can shrink …

This is an early-stage study testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific genetic change called KRAS G12D. Doctors will collect a patient's own immune cells, genetically modify them in a lab to recognize and attack can…

This is an early-stage safety study testing a new drug called azirkitug, both alone and in combination with other cancer therapies. It aims to find safe doses and understand how the drug moves through the body in adults with advanced solid tumors like lung, head and neck, and sev…

This early-stage study is testing a new immunotherapy drug called JANX008 in adults with advanced or spreading solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug shows any signs of fighting the cancer. Abou…

This study is testing a new targeted drug called divarasib, both alone and in combination with other cancer therapies, for people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and has not yet been treated. The main goals are to see how safe the…

This study is testing a focused, high-dose radiation treatment for people with lung tumors from non-small cell lung cancer or cancers that have spread to the lungs. Instead of daily treatments for weeks, participants receive 3-10 concentrated sessions over 1-2 weeks. The goal is …

This early-stage study is testing whether a new drug called ANK-101, when combined with standard immunotherapy, can help control advanced non-small cell lung cancer. It will enroll 60 participants, including both patients who have already tried immunotherapy and those who haven't…

This study is for people with advanced non-small cell lung cancer who have a specific genetic change (EGFR mutation). It tests if adding a second drug (sacituzumab tirumotecan) to their current medication (osimertinib) helps control the cancer better. The decision to add the seco…

This early-phase study tests a new imaging drug called [18F]DK222 in 6 people with lung or bladder cancer. The drug is designed to attach to PD-L1, a protein that helps cancer hide from the immune system. Researchers want to see if the drug is safe, how it moves through the body,…

This study is testing a new type of PET scan that uses a special tracer to find non-small cell lung cancer that has spread to the brain. About 20 adults with this condition will receive the tracer and then have a PET/CT scan. The goal is to see if this scan can detect cancer spot…

This early study tests a special PET imaging agent that targets a protein called IFN-y to see if it can spot non-small cell lung cancer and show how well the cancer responds to immunotherapy. Six people newly diagnosed with lung cancer will get a PET scan before and about 30 days…

This study tests a new type of PET scan that uses a special probe (68Ga-TOI-1) to target a protein called CDH3, found only on cancer cells. The goal is to see if this scan can detect and stage lung tumors better than the standard FDG-PET scan. About 80 adults with suspected or co…

This study tests whether a special PET scan and a fluorescent dye can help surgeons see exactly where lung cancer remains after chemotherapy or immunotherapy. About 200 people with stage II-IIIB lung cancer will receive the imaging before and during surgery. The goal is to improv…

This study looks at whether a special microscope called CLE can help doctors find non-small cell lung cancer (NSCLC) while doing a biopsy. About 70 people with suspected lung tumors will have the extra imaging during their standard procedure. The goal is to see if CLE can give a …

This early study tests a new radioactive imaging agent called FL-261 in 12 people with advanced lung, colorectal, or head & neck cancer. The goal is to see if it can safely and accurately find tumors and their spread, compared to standard scans. If successful, it may offer a non-…

This study looks at whether adding fermented foods (like yogurt, kimchi, and sauerkraut) to the diet can improve quality of life and treatment response in people with rectal or lung cancer. About 54 participants will either eat these foods regularly or follow their usual diet. Re…

This study looks at whether an 8-week pulmonary rehabilitation program can improve breathing, tiredness, and quality of life for people with advanced non-small cell lung cancer. Half of the 85 participants will do the rehab program, while the other half gets usual care. Researche…

This study compares two ways to help people recover from lung cancer surgery: in-person breathing exercises with a physiotherapist, or using a smartphone app (Fissios App) alongside those sessions. The goal is to see if the app reduces complications after surgery. About 560 adult…

This study tests a 12-week home-based coaching program for people who had surgery for early-stage lung cancer. Participants get a fitness tracker, a smartphone app, and coach calls to help them increase their daily steps. The goal is to see if this program improves physical activ…

This study compares how patients feel after two different minimally invasive surgeries for early-stage lung cancer: segmentectomy (removing only part of a lung lobe) and lobectomy (removing an entire lobe). Researchers will track breathing problems, physical function, and overall…

This study is testing whether a supervised exercise program is safe and doable for people with lung cancer who are getting radiation and chemotherapy. Ten participants will do breathing exercises, walking or cycling, and light strength training during their treatment. The goal is…

This study looks at whether a simple exercise program is practical and helpful for people with non-small cell lung cancer who are getting radiation therapy, along with their family caregivers. About 40 pairs (patient and caregiver) will take part. The goal is to see if the progra…

This study tests whether a special immune-boosting nutrition drink can lower the chance of severe throat and esophagus inflammation (esophagitis) in lung cancer patients getting chest radiation. About 121 adults with lung cancer will either receive standard care or the immunonutr…

This study tests a new radiation technique called lattice radiation therapy (LRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT works better than standard radiation at shrinking tumors and helping the immune system attack cancer cells. A…

This study is testing a new way to remove early-stage lung cancer using 3D computer models and a special dye that helps surgeons see the tumor during surgery. The goal is to make the operation more precise, reduce complications, and help patients recover faster. About 32 people w…

This study tests whether online singing training can help people who still have symptoms like shortness of breath and low energy 6 to 18 months after lung cancer surgery. About 100 participants will either join online singing sessions or continue with usual care. The goal is to s…

This study tests a new way to perform robotic lung surgery for early-stage lung cancer. Surgeons use a special dye that makes healthy lung tissue glow green, so they can see exactly which part to remove and which to save. The goal is to remove only the small cancerous segment ins…

This study tests a mobile app that guides lung cancer patients and their caregivers through yoga exercises at home. The goal is to see if the app is safe, easy to use, and helpful during radiation treatment. About 60 patient-caregiver pairs will participate.

This study tests whether a new version of megestrol acetate (nanocrystalline) can help people with advanced lung cancer maintain their appetite and body weight while undergoing chemotherapy and radiation. About 134 participants will receive either the drug or a placebo alongside …

This study looks at why ROS1-positive non-small cell lung cancer stops responding to the drug entrectinib. Researchers will analyze tumor or blood samples from 38 patients who have already taken entrectinib as part of their regular care. The goal is to identify genetic changes th…

This study looks at biological signs of aging in patients 70 and older with early-stage lung cancer. Researchers want to see if these markers can predict who will have complications or need hospitalization. The goal is to tailor treatments more safely for older adults.

This study tests whether a natural compound called urolithin A can improve the immune response in people with solid tumors (like lung cancer or melanoma) who are starting immunotherapy. About 45 participants will receive either urolithin A or a placebo alongside their standard tr…

This study is gathering samples (blood, urine, and bone marrow) from 320 people, including those with solid cancers like lung or colorectal cancer and those undergoing lung cancer screening. The goal is to detect tiny amounts of tumor cells and DNA to better understand how cancer…

This study looks at lung cancer tumors before and after two weeks of targeted therapy. By comparing the tumors, researchers hope to find early signs of drug resistance. The goal is to develop better combination treatments that can stop resistance before it starts. About 100 adult…

This study is testing whether an artificial intelligence tool can help connect cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to ma…

This study looks at the variety of bacteria in the gut of people with advanced non-small cell lung cancer. Researchers want to see if the types of gut bacteria are linked to how well treatment works or what side effects occur. About 82 participants will provide stool samples befo…

This study is testing a new, non-invasive technology called an electronic nose (E-nose) that analyzes chemicals in a person's breath. Researchers want to see if it can accurately measure how well lung cancer responds to standard treatment and if the cancer comes back later. About…

This study aims to understand why some lung cancers stop responding to the drug amivantamab. Researchers will collect blood and tumor samples from 30 adults with advanced non-small cell lung cancer that has a specific EGFR mutation. The goal is to find genetic changes that cause …

This study uses computer models to analyze data from over 144,000 people with advanced non-small cell lung cancer. The goal is to find which existing treatments work best for different patients, improving survival and quality of life. No new drugs are tested; instead, the study a…

This study is collecting blood samples and health information from 1,200 people with non-small cell lung cancer. Researchers want to understand how the cancer changes during standard treatment and whether simple blood tests can help predict if the cancer will come back. Participa…

This study aims to see if DNA changes in rectal mucus can signal the presence of certain cancers, including lung, pancreatic, bladder, and colorectal cancers. Researchers will collect samples from 450 adults using a special device. The goal is to understand if this non-invasive m…

This study looks at patients whose lung cancer came back after they already had a type of high-precision radiation called SBRT. Since surgery is not an option for many, doctors want to know if giving SBRT again is safe and works. The study will review past cases from multiple hos…

This study uses a survey to find out what factors are most important to Chinese patients and doctors when choosing a first-line targeted therapy for advanced lung cancer. About 590 participants (patients and physicians) will answer questions about treatment preferences. The goal …

This study will collect tumor and blood samples from 1100 people with various cancers (like head and neck, ovarian, and lung cancer) to measure how active certain immune cells (T cells) are. The goal is to learn more about why some cancers trigger a stronger immune response than …

This study looks at whether the type of anesthesia used during lung cancer surgery can influence whether the cancer comes back. About 5,384 people having surgery for early-stage non-small cell lung cancer will be randomly assigned to receive either inhaled gas anesthesia or intra…

This study looks at whether measuring the amount of pembrolizumab in the blood can help predict how well it works and what side effects occur in people with non-small cell lung cancer. About 75 adults already receiving pembrolizumab will have their drug levels checked and linked …

This study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand which cancers lose a specific marker (HLA) and to store participants' own T cells for possible future CAR T-cell ther…

This study watches 100 adults with advanced non-small cell lung cancer who have certain EGFR gene changes and are already getting amivantamab plus chemotherapy through an early access program. Researchers want to see how long the cancer stays under control in real life, without a…

This study is for people with advanced colorectal or non-small cell lung cancer. It compares two approaches: one where doctors use both standard scans and a special blood test (ctDNA) to monitor the cancer, and another where only standard scans are used. The goal is to see if add…

This study looks at the biological makeup of a specific type of lung cancer (ALK-positive) in 100 adults with advanced disease. Researchers will analyze tumor tissue and blood samples taken at diagnosis and when the cancer progresses. The goal is to learn how the cancer changes o…

This study is collecting blood samples and medical information from 500 adults diagnosed with lung cancer at age 45 or younger. The goal is to build a large registry of samples and data to help researchers understand what causes lung cancer in younger people and find new ways to …

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study looks at how the drug osimertinib is used in real-life settings for people with a specific type of lung cancer (EGFR-mutated non-small cell lung cancer) in Spain. Researchers will collect information from about 500 patients to see how well the drug works, how long peop…

This study tracks about 538 people with advanced EGFR-mutated non-small cell lung cancer who are receiving standard treatment (osimertinib with or without chemotherapy) as part of their regular care. The goal is to see how long the treatment keeps the cancer from growing and how …

This study does not test a new treatment. Instead, it collects information from 550 adults with advanced lung cancer who have already had chemotherapy. The goal is to create a control group using real-world data, which can help future studies compare new treatments more accuratel…

This study looks at 300 people with early-stage lung cancer to understand why some tumors grow differently. Researchers will analyze genes, immune cells, and other molecules from tumor samples. The goal is to find new ways to predict which cancers might come back and identify pot…

This study collects tumor samples, blood, and health information from 2,000 adults with certain lung and thymic cancers. The goal is to better understand these diseases and support research into new treatments. Participants provide samples and may have scans, with yearly follow-u…

This study is for people with kidney, bladder, lung, or liver cancer who are about to start immunotherapy (PD-1/PDL-1 inhibitors). Researchers want to see if levels of a protein called Galectin-3 in the blood are linked to how well the treatment works and what side effects occur.…

This study looks at 60 adults with early-stage non-small cell lung cancer whose cancer came back after surgery and treatment with the drug osimertinib. Researchers will analyze tumor or blood samples to find gene changes linked to the recurrence. The goal is to better understand …

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers grow and why they respond differently to treatments. The goal is to develop more effective therapi…

This study follows 130 people with a specific type of advanced lung cancer (EGFR mutant NSCLC) who are starting a standard drug called osimertinib. Researchers want to see how long the drug controls the cancer in real-world settings, not just in controlled trials. Participants pr…

This study looks at whether changes in a blood marker called ctDNA can help doctors know early on if immunotherapy is working for people with advanced cancers like lung, breast, or colorectal cancer. About 50 adults with stage IV cancer who are starting immunotherapy will give bl…

This study follows 500 adults with advanced non-small cell lung cancer who are prescribed cemiplimab (Libtayo) as part of their normal care in Europe. Researchers will track how long patients live, how well the cancer responds, and any side effects. The goal is to see how the dru…

This study is observing 500 adults aged 70 and older with non-small cell lung cancer who are starting their first standard treatment. Researchers will track how well the treatments work, side effects, and impact on quality of life. The goal is to gather real-world data to better …

This study aims to understand cancer-related fatigue in 20 adults with non-small cell lung cancer who are receiving immunotherapy. Researchers will conduct interviews and use questionnaires to learn about fatigue patterns, daily impacts, and patients' views on physical activity. …

This study looks at whether a lab-grown model made from a patient's own lung cancer cells can help doctors choose the most effective drugs. Researchers will compare the model's predictions to how the patient actually responds to treatment. About 250 adults with non-small cell lun…

This study aims to collect genetic information from 550 people in Taiwan with advanced non-small cell lung cancer. Researchers will analyze tumor samples to understand why some patients stop responding to current treatments. The goal is to create a detailed genetic map to help de…